Advances in melanoma senescence and potential clinical application

Authors

  • Sandy Giuliano,

    1.  Inserm, U895, Equipe 1, Biologie et Pathologies des Mélanocytes: de la Pigmentation Cutanée au Mélanome, C3M, Nice, France
    2.  Université of Nice Sophia-Antipolis, UFR Médecine, Nice, France
    Search for more papers by this author
  • Mickaël Ohanna,

    1.  Inserm, U895, Equipe 1, Biologie et Pathologies des Mélanocytes: de la Pigmentation Cutanée au Mélanome, C3M, Nice, France
    2.  Université of Nice Sophia-Antipolis, UFR Médecine, Nice, France
    Search for more papers by this author
  • Robert Ballotti,

    1.  Inserm, U895, Equipe 1, Biologie et Pathologies des Mélanocytes: de la Pigmentation Cutanée au Mélanome, C3M, Nice, France
    2.  Université of Nice Sophia-Antipolis, UFR Médecine, Nice, France
    3.  Centre Hospitalier Universitaire de Nice, Service de Dermatologie, Nice, France
    Search for more papers by this author
  • Corine Bertolotto

    1.  Inserm, U895, Equipe 1, Biologie et Pathologies des Mélanocytes: de la Pigmentation Cutanée au Mélanome, C3M, Nice, France
    2.  Université of Nice Sophia-Antipolis, UFR Médecine, Nice, France
    3.  Centre Hospitalier Universitaire de Nice, Service de Dermatologie, Nice, France
    Search for more papers by this author

C. Bertolotto, e-mail: bertolot@unice.fr

Summary

Normal cells possess a limited proliferative life span, after which they enter a state of irreversible growth arrest, called replicative senescence, which acts as a potent barrier against transformation. Transformed cells have escaped the process of replicative senescence and theoretically can not re-enter senescence. However, recent observations showed that transformed cells, and particularly the melanoma cells, can still undergo oncogene or stress-induced senescence. This senescence state is accompanied by many of the markers associated with replicative senescence, such as flattened shape, increased acidic β-galactosidase activity, characteristic changes in gene expression and growth arrest. Interestingly, in some cancers, senescence induction following chemotherapy has been correlated with a favorable patient outcome. In this review, we gathered recent results describing senescence-like phenotype induction in melanoma cells and discuss why senescence may also be exploited as a therapeutic strategy in melanoma.

Ancillary